If approved by the European Fee, fezolinetant can be a nonhormonal therapy for average to extreme vasomotor signs related to menopause
TOKYO, Sept. 29, 2022 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) at present introduced the European Medicines Company (EMA) has accepted for regulatory evaluate the corporate’s advertising authorization utility (MAA) for fezolinetant, an investigational oral, nonhormonal compound looking for approval for the therapy of average to extreme vasomotor signs (VMS) related to menopause. VMS, characterised by sizzling flashes and/or night time sweats, are frequent signs of menopause.1,2
“Greater than half of ladies 40 to 64 years of age expertise sizzling flashes throughout menopause, with restricted nonhormonal therapy choices,” mentioned Ahsan Arozullah, M.D., M.P.H., Senior Vice President and Head of Growth Therapeutic Areas, Astellas. “The EMA’s acceptance of our MAA for fezolinetant brings us one step nearer to advancing a possible first-in-class nonhormonal therapy choice for girls in Europe who expertise VMS related to menopause, just like the FDA acceptance of our NDA for girls within the U.S.”
The MAA is supported by outcomes from the BRIGHT SKY™ program, which included three Section 3 medical trials that collectively enrolled over 2,800 girls with VMS throughout Europe, the U.S. and Canada. Outcomes from the SKYLIGHT 1™ and SKYLIGHT 2™ pivotal trials characterize the efficacy and security of fezolinetant for the therapy of average to extreme VMS related to menopause. Information from the SKYLIGHT 4™ security examine additional characterizes the long-term security profile of fezolinetant. Throughout the MAA, Astellas proposes a forty five mg each day dose, which is topic to the EMA’s evaluate.
Fezolinetant is an investigational nonhormonal selective neurokinin 3 (NK3) receptor antagonist. The protection and efficacy of fezolinetant are beneath investigation and haven’t been established.
This acceptance may have no influence on Astellas’ monetary forecasts of the present fiscal 12 months ending March 31, 2023.
In regards to the BRIGHT SKY™ Section 3 Program
The BRIGHT SKY pivotal trials, SKYLIGHT 1™ (NCT04003155) and SKYLIGHT 2™ (NCT04003142), enrolled over 1,000 girls with average to extreme VMS. The trials are double-blinded, placebo-controlled for the primary 12 weeks adopted by a 40-week therapy extension interval. Girls have been enrolled at over 180 websites inside the U.S., Canada and Europe. SKYLIGHT 4™ (NCT04003389) is a 52-week double-blinded, placebo-controlled examine designed to analyze the long-term security of fezolinetant. For SKYLIGHT 4, over 1,800 girls with VMS have been enrolled at over 180 websites inside the U.S., Canada and Europe.
About VMS Related to Menopause
VMS, characterised by sizzling flashes (additionally known as sizzling flushes) and/or night time sweats, are frequent signs of menopause.1,2 Worldwide, greater than half of ladies 40 to 64 years of age expertise VMS with charges in Europe starting from 56% to 97%.3,4,5 The prevalence of average to extreme VMS in postmenopausal girls in Europe has been reported at 40%.6 VMS can have a disruptive influence on girls’s each day actions and total high quality of life.1
Fezolinetant is an investigational oral, nonhormonal remedy in medical growth for the therapy of average to extreme VMS related to menopause. Fezolinetant works by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin/dynorphin (KNDy) neuron to average neuronal exercise within the thermoregulatory heart of the mind (the hypothalamus) to cut back the frequency and severity of average to extreme VMS related to menopause.7,8,9 The protection and efficacy of fezolinetant are beneath investigation and haven’t been established. There isn’t any assure the agent will obtain regulatory approval or turn into commercially out there for the makes use of being investigated.
Astellas Pharma Inc. is a pharmaceutical firm conducting enterprise in additional than 70 international locations around the globe. We’re selling the Focus Space Method that’s designed to determine alternatives for the continual creation of latest medicine to handle ailments with excessive unmet medical wants by specializing in Biology and Modality. Moreover, we’re additionally wanting past our foundational Rx focus to create Rx+® healthcare options that mix our experience and data with cutting-edge know-how in several fields of exterior companions. By means of these efforts, Astellas stands on the forefront of healthcare change to show revolutionary science into worth for sufferers. For extra info, please go to our web site at https://www.astellas.com/en.
On this press launch, statements made with respect to present plans, estimates, methods and beliefs and different statements that aren’t historic details are forward-looking statements concerning the future efficiency of Astellas. These statements are based mostly on administration’s present assumptions and beliefs in gentle of the data presently out there to it and contain identified and unknown dangers and uncertainties. A lot of elements might trigger precise outcomes to vary materially from these mentioned within the forward-looking statements. Such elements embody, however aren’t restricted to: (i) modifications usually financial circumstances and in legal guidelines and laws, referring to pharmaceutical markets, (ii) forex trade fee fluctuations, (iii) delays in new product launches, (iv) the shortcoming of Astellas to market present and new merchandise successfully, (v) the shortcoming of Astellas to proceed to successfully analysis and develop merchandise accepted by prospects in extremely aggressive markets, and (vi) infringements of Astellas’ mental property rights by third events. Details about pharmaceutical merchandise (together with merchandise presently in growth) which is included on this press launch just isn’t supposed to represent an commercial or medical recommendation.
1 Utian WH. Psychosocial and socioeconomic burden of vasomotor signs in menopause: a complete evaluate. Well being Qual Life Outcomes. 2005;3:47.
2 Jones RE, Lopez KH, eds. Human Reproductive Biology. 4th ed. Waltham, MA: Elsevier, 2014:120.
3 Makara-Studzinska MT, Krys-Noszczyk KM, Jakiel G. Epidemiology of the signs of menopause – an intercontinental evaluate. Przegl Menopauzalny [Menopause Rev]. 2014;13:203-211.
4 Gold EB, Colvin A, Avis N, et al. Longitudinal evaluation of the affiliation between vasomotor signs and race/ethnicity throughout the menopausal transition: examine of ladies’s well being throughout the nation. Am J Public Well being. 2006;96:1226-1235.
5 Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor signs amongst peri- and postmenopausal girls in the US. Climacteric. 2008;11:32-43.
6 Nappi RE, Kroll R, Siddiqui E, et al. World cross-sectional survey of ladies with vasomotor signs related to menopause: prevalence and high quality of life burden. Menopause. 2021;28:875-882.
7 Depypere H, Timmerman D, Donders G, et al. Remedy of menopausal vasomotor signs with fezolinetant, a neurokinin 3 receptor antagonist: a section 2a trial. J Clin Endocrinol Metab. 2019;104:5893-5905.
8 Fraser GL, Lederman S, Waldbaum A, et al. A section 2b, randomized, placebo-controlled, double-blind, dose-ranging examine of the neurokinin 3 receptor antagonist fezolinetant for vasomotor signs related to menopause. Menopause. 2020;27:382-392.
9 Fraser GL, Hoveyda HR, Clarke IJ, et al. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and average ranges of ovarian hormones all through the menstrual cycle. Endocrinology. 2015;156:4214-4225.
SOURCE Astellas Pharma Inc.